ABBV-787 / AbbVie - LARVOL DELTA

Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - P1 | N=36 | Terminated | Sponsor: AbbVie | N=60 ➔ 36 | Trial completion date: Oct 2029 ➔ Feb 2025 | Recruiting ➔ Terminated | Trial primary completion date: Oct 2029 ➔ Feb 2025; Strategic considerations

Adverse events • Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Expanded Access to ABBV-787 (clinicaltrials.gov) - P=N/A | N=0 | Available | Sponsor: AbbVie

New trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: AbbVie | Not yet recruiting ➔ Recruiting

Adverse events • Enrollment open • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: AbbVie

Adverse events • New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology